Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Vornado, Ken Griffin and Rudin Close 350 Park Avenue Joint Venture

Vornado, Ken Griffin and Rudin Close 350 Park Avenue Joint Venture

BitgetBitget2026/10/21 13:10
  • Vornado Realty Trust closed a joint venture with Ken Griffin and Rudin to develop 350 Park Avenue in Manhattan.
  • A Griffin affiliate owns 60% of the venture, with Vornado holding 36% and Rudin 4%.
  • The venture secured a $3.3 billion construction loan.
  • Citadel Enterprise Americas signed a 1.05 million-square-foot anchor lease; 850,000 square feet will be available to the market.
  • Construction is underway on the 66-story tower, which will deliver more than 1.9 million square feet.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vornado Realty Trust published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210909PRIMZONEFULLFEED9850439) on October 21, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GM cancels long-term rare earth permanent magnet supply agreement in the US; supplier initiates arbitration

General Motors (GM.US) has canceled a long-term supply agreement with a U.S. rare earth permanent magnet manufacturer, and both parties are currently undergoing arbitration.

智通财经•2026/10/23 03:27
GM cancels long-term rare earth permanent magnet supply agreement in the US; supplier initiates arbitration

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.

Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.

智通财经•2026/10/23 02:47